Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant adebrelimab + recatisibiumab + chemotherapy for resectable esophageal squamous cell carcinoma
ChiCTR2500102709Phase 2Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- May 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of adebrelimab, paclitaxel and carboplatin in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: Pathological complete remission rate. Planned start May 2025; status: not yet recruiting.
02
Drugs
adebrelimabpaclitaxelcarboplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2500102709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102709.